Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 3/20 | 0.49 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.49 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | APLNR | P35414 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL541 | 0.84 | AGTR1 (0.69) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL986257 | 0.84 | GP6 (0.48) | AGTR1AGTR2APLNRPPARG | |
| SCHEMBL12716746 | 0.79 | PPARG (0.60) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL10589345 | 0.78 | PPARG (0.59) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL2927903 | 0.78 | AGTR1 (0.49) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Hydrochloric Acid SCHEMBL524 | 0.78 | PPARG (0.58) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL29032842 | 0.78 | PPARG (0.58) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL559 | 0.77 | AGTR1 (0.43) | AGTR1AGTR2 | |
| SCHEMBL8229075 | 0.77 | AGTR2 (0.52) | AGTR1AGTR2 | |
| SCHEMBL9016466 | 0.76 | APLNR (0.44) | AGTR1AGTR2APLNRPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868180-B2 | Process for the preparation of sartan derivatives and intermediates useful in such process | KRKA, D.D. NOVO MESTO (SI) | 2011-01-11 | — | — | US | disclosed |
| EP-1589966-B1 | PREPARATION OF NEW PHARMACEUTICALLY SUITABLE SALT OF LOSARTAN AND FORMS THEREOF WITH NEW PURIFICATION AND ISOLATION METHODS | LEK PHARMACEUTICALS (SI) | 2010-11-10 | — | — | EP | disclosed |
| US-20080312451-A1 | Process For the Preparation of Sartan Derivatives and Intermediates Useful in Such Process | KRKA, D.D. NOVO MESTO (SK) | 2008-12-18 | — | — | US | disclosed |
| WO-2007119246-A2 | AN IMPROVED PROCESS FOR THE MANUFACTURE OF LOSARTAN POTASSIUM | UNICHEM LABORATORIES LIMITED (IN) | 2007-10-25 | — | — | WO | disclosed |
| US-7271269-B2 | Stability, purity, potassium salt of losartan in crystal Form X, as anti-hypertensive agent | LEK PHARMACEUTICALS D.D. (SI) | 2007-09-18 | — | — | US | disclosed |
| EP-1764365-A1 | A process for the preparation of sartan derivates and intermediates useful in such process | KRKA, D.D., Novo Mesto (SI) | 2007-03-21 | — | — | EP | disclosed |
| US-20060004207-A1 | Preparation of new pharmaceutically suitable salt of losartan and forms thereof with new purification and isolation methods | LEK PHARMACEUTICALS D.D. (SI) | 2006-01-05 | — | — | US | disclosed |
| EP-1589966-A2 | PREPARATION OF NEW PHARMACEUTICALLY SUITABLE SALT OF LOSARTAN AND FORMS THEREOF WITH NEW PURIFICATION AND ISOLATION METHODS | LEK Pharmaceuticals D.D. (SI) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004066997-A2 | PREPARATION OF NEW PHARMACEUTICALLY SUITABLE SALT OF LOSARTAN AND FORMS THEREOF WITH NEW PURIFICATION AND ISOLATION METHODS | LEK PHARMACEUTICALS D.D. (SI) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312451-A1 | Process For the Preparation of Sartan Derivatives and Intermediates Useful in Such Process | MC5R, NPY5R, ADRA1D | AGTR1 283/4885AGTR2 311/4885ABCC4 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.